NEUP (Neuphoria Therapeutics) Total Liabilities : $4.42 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Neuphoria Therapeutics Total Liabilities?

Neuphoria Therapeutics's Total Liabilities for the quarter that ended in Dec. 2024 was $4.42 Mil.

Neuphoria Therapeutics's quarterly Total Liabilities declined from Jun. 2024 ($10.16 Mil) to Sep. 2024 ($5.85 Mil) and declined from Sep. 2024 ($5.85 Mil) to Dec. 2024 ($4.42 Mil).

Neuphoria Therapeutics's annual Total Liabilities increased from Jun. 2022 ($5.78 Mil) to Jun. 2023 ($6.55 Mil) and increased from Jun. 2023 ($6.55 Mil) to Jun. 2024 ($10.16 Mil).

Neuphoria Therapeutics Total Liabilities Historical Data

The historical data trend for Neuphoria Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuphoria Therapeutics Total Liabilities Chart

Neuphoria Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Liabilities

Get a 7-Day Free Trial

14.97

5.01

5.78

6.55

10.16

Neuphoria Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															-	6.69	10.16	5.85	4.42

Neuphoria Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Neuphoria Therapeutics's Total Liabilities for the fiscal year that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3.829	+	(0.118	+	5.248
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0.964	+	0	+	0)
	=	10.16

Total Liabilities	=	Total Assets (A: Jun. 2024 )	-	Total Equity (A: Jun. 2024 )
	=	27.649	-	17.49
	=	10.16

Neuphoria Therapeutics's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.134	+	(0.05	+	1.393
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0.843	+	0	+	0)
	=	4.42

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	18.168	-	13.748
	=	4.42

Neuphoria Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Neuphoria Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuphoria Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuphoria Therapeutics Inc (NAS:NEUP) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Summit Dr, Burlington, MA, USA, 01803

Website

https://www.bionomics.com.au

Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.